Dementia Translational Research Collaboration
The NIHR Dementia Translational Research Collaboration (TRC) provides a network of world-leading investigators who are available to work with industry to further research and develop new treatments for dementia.
Our researchers are experts in translating new discoveries in dementia research from basic science into the clinic, and can provide access to patients from multiple sites across the UK.
The Dementia TRC is open to developing partnerships with companies to carry out experimental medicine investigations in:
- Late-onset dementias, including Alzheimer's Disease, vascular disease and Lewy body dementia
- Young-onset dementias
- Frontotemporal dementia with motor neuron disease
- Parkinson's disease, including progression to dementia
- Huntington's Disease
These investigations focus on biomarker discovery and validation, early diagnosis, patient stratification, phase I and phase II experimental medicine and proof of concept trials. The Dementia TRC also boasts a wealth of expertise in investigating novel technologies and devices, including in the wearables and AI fields, as tools for diagnosing, monitoring and treatment;
For more information please visit the NIHR Dementia Translational Research Collaboration website.
Who is this for?
The Dementia TRC undertakes commercial and non-commercial studies with industry and academic partners. It is open to collaborations with any life sciences company, including pharmaceutical and diagnostic companies as well as academic institutions. It will consider fully-funded projects as well as projects that will look for third party funding.
Benefits of working with the Dementia TRC
- Opportunities to develop collaborations with academia and industry in a pre-competitive space.
- The TRC provides easy, coordinated access to a network of academic centres and experts embedded in UK universities and NHS hospitals who are available to work collaboratively on early phase clinical studies in dementia.
- The TRC centres operate to standardised capabilities and standard operating procedures across a number of sites to facilitate multi-centre studies. This makes it quicker and easier for industry to work with relevant expert investigators.
- The TRC provides operational support, including a standard pre-approved non-disclosure agreement, contractual templates and a close working relationship with the NIHR Clinical Research Network for identification of sites.
Read how the NIHR Dementia Translational Research Collaboration has collaborated with industry:
To find out more about the NIHR Dementia TRC and how your company or organisation can collaborate with us. E-mail: firstname.lastname@example.org
- For more information please visit the NIHR Dementia Translational Research Collaboration website
News: NIHR launches campaign to highlight UK expertise in delivering complex and innovative trials News: Life Sciences Sector Deal 2: Competition underway to host five new Patient Recruitment Centres (PRCs) News: New report highlights how NIHR support for clinical research benefits the UK economy and NHS
Latest news about Dementias and Neurodegeneration
News: NIHR launches campaign to highlight UK expertise in delivering complex and innovative trials
News: Life Sciences Sector Deal 2: Competition underway to host five new Patient Recruitment Centres (PRCs)
News: New report highlights how NIHR support for clinical research benefits the UK economy and NHS